European guidelines on managing adverse effects of medication for ADHD

J. Graham; T. Banaschewski; J. Buitelaar; D. Coghill; M. Danckaerts; Ralf W Dittmann; M. Doepfner; R. Hamilton; C. Hollis; M. Holtmann; M. Hulpke-Wette; M. Lecendreux; E. Rosenthal; A. Rothenberger; P. Santosh; J. Sergeant; E. Simonoff; E. Sonuga-Barke; I. C. K. Wong; A. Zuddas; H. -C. Steinhausen; E. Taylor; European Guidelines Grp

doi:10.1007/s00787-010-0140-6

European guidelines on managing adverse effects of medication for ADHD

J. Graham (Lead / Corresponding author), T. Banaschewski, J. Buitelaar, D. Coghill, M. Danckaerts, Ralf W Dittmann, M. Doepfner, R. Hamilton, C. Hollis, M. Holtmann, M. Hulpke-Wette, M. Lecendreux, E. Rosenthal, A. Rothenberger, P. Santosh, J. Sergeant, E. Simonoff, E. Sonuga-Barke, I. C. K. Wong, A. ZuddasH. -C. Steinhausen, E. Taylor, European Guidelines Grp

Research output: Contribution to journal › Article › peer-review

306 Citations (Scopus)

Abstract

The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical sub-specialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.

Original language	English
Pages (from-to)	17-37
Number of pages	21
Journal	European Child & Adolescent Psychiatry
Volume	20
Issue number	1
DOIs	https://doi.org/10.1007/s00787-010-0140-6
Publication status	Published - Jan 2011

Keywords

ADHD
HKS
Medication
Adverse
Guidelines
European
Children
ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER
DEFICIT-HYPERACTIVITY DISORDER
SUBSTANCE USE DISORDERS
SUDDEN CARDIAC DEATH
RANDOMIZED CONTROLLED-TRIAL
COMORBID TIC DISORDERS
PEDIATRIC BURN INJURY
PROSPECTIVE FOLLOW-UP
OF-THE-LITERATURE
YOUNG-ADULTS

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00787-010-0140-6

Cite this

Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Doepfner, M., Hamilton, R., Hollis, C., Holtmann, M., Hulpke-Wette, M., Lecendreux, M., Rosenthal, E., Rothenberger, A., Santosh, P., Sergeant, J., Simonoff, E., Sonuga-Barke, E., Wong, I. C. K., ... European Guidelines Grp (2011). European guidelines on managing adverse effects of medication for ADHD. European Child & Adolescent Psychiatry, 20(1), 17-37. https://doi.org/10.1007/s00787-010-0140-6

@article{b7a9b3a050c5485081fa0b5ff7088c76,

title = "European guidelines on managing adverse effects of medication for ADHD",

abstract = "The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical sub-specialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.",

keywords = "ADHD, HKS, Medication, Adverse, Guidelines, European, Children, ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER, DEFICIT-HYPERACTIVITY DISORDER, SUBSTANCE USE DISORDERS, SUDDEN CARDIAC DEATH, RANDOMIZED CONTROLLED-TRIAL, COMORBID TIC DISORDERS, PEDIATRIC BURN INJURY, PROSPECTIVE FOLLOW-UP, OF-THE-LITERATURE, YOUNG-ADULTS",

author = "J. Graham and T. Banaschewski and J. Buitelaar and D. Coghill and M. Danckaerts and Dittmann, {Ralf W} and M. Doepfner and R. Hamilton and C. Hollis and M. Holtmann and M. Hulpke-Wette and M. Lecendreux and E. Rosenthal and A. Rothenberger and P. Santosh and J. Sergeant and E. Simonoff and E. Sonuga-Barke and Wong, {I. C. K.} and A. Zuddas and Steinhausen, {H. -C.} and E. Taylor and {European Guidelines Grp}",

year = "2011",

month = jan,

doi = "10.1007/s00787-010-0140-6",

language = "English",

volume = "20",

pages = "17--37",

journal = "European Child & Adolescent Psychiatry",

issn = "1018-8827",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

Graham, J, Banaschewski, T, Buitelaar, J, Coghill, D, Danckaerts, M, Dittmann, RW, Doepfner, M, Hamilton, R, Hollis, C, Holtmann, M, Hulpke-Wette, M, Lecendreux, M, Rosenthal, E, Rothenberger, A, Santosh, P, Sergeant, J, Simonoff, E, Sonuga-Barke, E, Wong, ICK, Zuddas, A, Steinhausen, H-C, Taylor, E & European Guidelines Grp 2011, 'European guidelines on managing adverse effects of medication for ADHD', European Child & Adolescent Psychiatry, vol. 20, no. 1, pp. 17-37. https://doi.org/10.1007/s00787-010-0140-6

TY - JOUR

T1 - European guidelines on managing adverse effects of medication for ADHD

AU - Graham, J.

AU - Banaschewski, T.

AU - Buitelaar, J.

AU - Coghill, D.

AU - Danckaerts, M.

AU - Dittmann, Ralf W

AU - Doepfner, M.

AU - Hamilton, R.

AU - Hollis, C.

AU - Holtmann, M.

AU - Hulpke-Wette, M.

AU - Lecendreux, M.

AU - Rosenthal, E.

AU - Rothenberger, A.

AU - Santosh, P.

AU - Sergeant, J.

AU - Simonoff, E.

AU - Sonuga-Barke, E.

AU - Wong, I. C. K.

AU - Zuddas, A.

AU - Steinhausen, H. -C.

AU - Taylor, E.

AU - European Guidelines Grp

PY - 2011/1

Y1 - 2011/1

N2 - The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical sub-specialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.

AB - The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical sub-specialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.

KW - ADHD

KW - HKS

KW - Medication

KW - Adverse

KW - Guidelines

KW - European

KW - Children

KW - ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER

KW - DEFICIT-HYPERACTIVITY DISORDER

KW - SUBSTANCE USE DISORDERS

KW - SUDDEN CARDIAC DEATH

KW - RANDOMIZED CONTROLLED-TRIAL

KW - COMORBID TIC DISORDERS

KW - PEDIATRIC BURN INJURY

KW - PROSPECTIVE FOLLOW-UP

KW - OF-THE-LITERATURE

KW - YOUNG-ADULTS

U2 - 10.1007/s00787-010-0140-6

DO - 10.1007/s00787-010-0140-6

M3 - Article

C2 - 21042924

SN - 1018-8827

VL - 20

SP - 17

EP - 37

JO - European Child & Adolescent Psychiatry

JF - European Child & Adolescent Psychiatry

IS - 1

ER -

European guidelines on managing adverse effects of medication for ADHD

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this